A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy

NCT07669740 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer (Diagnosis)

Interventions

DRUG: Sintilimab Combined with Ramucirumab and Paclitaxel

Sponsor

The First Affiliated Hospital with Nanjing Medical University